Literature DB >> 26585409

Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) Program.

Clive Ballard1, Martin Orrell1, Sun YongZhong1, Esme Moniz-Cook1, Jane Stafford1, Rhiannon Whittaker1, Bob Woods1, Anne Corbett1, Lucy Garrod1, Zunera Khan1, Barbara Woodward-Carlton1, Jennifer Wenborn1, Jane Fossey1.   

Abstract

OBJECTIVE: This study evaluated the impact of antipsychotic review, social interaction, and exercise, in conjunction with person-centered care, on antipsychotic use, agitation, and depression in people with dementia living in nursing homes.
METHOD: A cluster-randomized factorial controlled trial with two replications was conducted in people with dementia in 16 U.K. nursing homes. All homes received training in person-centered care. Eight homes were randomly assigned to antipsychotic review, to a social interaction intervention, and to an exercise intervention for 9 months, with most homes assigned to more than one intervention. The primary outcome measures were antipsychotic use, agitation, and depression. Secondary outcome measures were overall neuropsychiatric symptoms and mortality.
RESULTS: Antipsychotic review significantly reduced antipsychotic use by 50% (odds ratio 0.17, 95% confidence interval [CI] 0.05 to 0.60). Antipsychotic review plus the social interaction intervention significantly reduced mortality (odds ratio 0.26, 95% CI 0.13 to 0.51) compared with the group receiving neither. The group receiving antipsychotic review but not the social intervention showed significantly worse outcome in neuropsychiatric symptoms compared with the group receiving neither (score difference +7.37, 95% CI 1.53 to 13.22). This detrimental impact was mitigated by concurrent delivery of the social intervention (-0.44, CI -4.39 to 3.52). The exercise intervention significantly improved neuropsychiatric symptoms (-3.59, 95% CI -7.08 to -0.09) but not depression (-1.21, CI -4.35 to 1.93). None of the interventions had a significant impact specifically on agitation.
CONCLUSIONS: While reductions in antipsychotic use can be achieved by using a "real world" intervention, this may not be of benefit to people with dementia in the current climate of more judicious prescribing unless nonpharmacological interventions such as social interaction or exercise are provided in parallel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26585409     DOI: 10.1176/appi.ajp.2015.15010130

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  30 in total

1.  Training for Direct Support Staff at Group Homes for People with Chronic Mental Illness.

Authors:  Alireza Amirsadri; Albert Pizzuti; Daicia Smith; Danielle Duckett; Cynthia L Arfken
Journal:  Community Ment Health J       Date:  2017-07-28

Review 2.  Antipsychotic Use in Dementia.

Authors:  Julia Kirkham; Chelsea Sherman; Clive Velkers; Colleen Maxwell; Sudeep Gill; Paula Rochon; Dallas Seitz
Journal:  Can J Psychiatry       Date:  2016-10-08       Impact factor: 4.356

3.  The National Partnership to Improve Dementia Care and Hospital Readmission Among Skilled Nursing Facility Residents.

Authors:  Sijiu Wang; Helena Temkin-Greener; Yeates Conwell; Shubing Cai
Journal:  J Appl Gerontol       Date:  2022-06-02

Review 4.  Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.

Authors:  Kenneth M Heilman; Stephen E Nadeau
Journal:  Neurotherapeutics       Date:  2022-01-10       Impact factor: 6.088

Review 5.  Clinical and Economic Outcomes of Interventions to Reduce Antipsychotic and Benzodiazepine Use Within Nursing Homes: A Systematic Review.

Authors:  Daniel J Hoyle; Ivan K Bindoff; Lisa M Clinnick; Gregory M Peterson; Juanita L Westbury
Journal:  Drugs Aging       Date:  2018-02       Impact factor: 3.923

6.  Cost-utility analysis of a consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients.

Authors:  Mireia Massot Mesquida; Frans Folkvord; Gemma Seda; Francisco Lupiáñez-Villanueva; Pere Torán Monserrat
Journal:  BMC Geriatr       Date:  2021-05-22       Impact factor: 3.921

Review 7.  Palliative care interventions in advanced dementia.

Authors:  Sharon C Walsh; Edel Murphy; Declan Devane; Elizabeth L Sampson; Sheelah Connolly; Patricia Carney; Eamon O'Shea
Journal:  Cochrane Database Syst Rev       Date:  2021-09-28

8.  Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study.

Authors:  Gill Livingston; Julie Barber; Louise Marston; Penny Rapaport; Deborah Livingston; Sian Cousins; Sarah Robertson; Francesca La Frenais; Claudia Cooper
Journal:  BJPsych Open       Date:  2017-07-27

Review 9.  Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.

Authors:  Krista L Lanctôt; Joan Amatniek; Sonia Ancoli-Israel; Steven E Arnold; Clive Ballard; Jiska Cohen-Mansfield; Zahinoor Ismail; Constantine Lyketsos; David S Miller; Erik Musiek; Ricardo S Osorio; Paul B Rosenberg; Andrew Satlin; David Steffens; Pierre Tariot; Lisa J Bain; Maria C Carrillo; James A Hendrix; Heidi Jurgens; Brendon Boot
Journal:  Alzheimers Dement (N Y)       Date:  2017-08-05

Review 10.  Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia.

Authors:  Ellen Van Leeuwen; Mirko Petrovic; Mieke L van Driel; An Im De Sutter; Robert Vander Stichele; Tom Declercq; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2018-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.